Use of Drug-eluting Stents Versus Bare-metal Stents in Korea: A Cost-minimization Analysis Using Population Data
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: The goal of this study was to perform an economic analysis of a primary stenting with drug-eluting stents (DES) compared with bare-metal stents (BMS) in patients with acute myocardial infarction (AMI) admitted through an emergency room (ER) visit in Korea using population-based data. Methods: We employed a cost-minimization method using a decision analytic model with a two-year time period. Model probabilities and costs were obtained from a published systematic review and population-based data from which a retrospective database analysis of the national reimbursement database of Health Insurance Review and Assessment covering 2006 through 2010 was performed. Uncertainty was evaluated using one-way sensitivity analyses and probabilistic sensitivity analyses. Results: Among 513 979 cases with AMI during 2007 and 2008, 24 742 cases underwent stenting procedures and 20 320 patients admitted through an ER visit with primary stenting were identified in the base model. The transition probabilities of DES-to-DES, DES-to-BMS, DES-to-coronary artery bypass graft, and DES-to-balloon were 59.7%, 0.6%, 4.3%, and 35.3%, respectively, among these patients. The average two-year costs of DES and BMS in 2011 Korean won were 11 065 528 won/person and 9 647 647 won/person, respectively. DES resulted in higher costs than BMS by 1 417 882 won/person. The model was highly sensitive to the probability and costs of having no revascularization. Conclusions: Primary stenting with BMS for AMI with an ER visit was shown to be a cost-saving procedure compared with DES in Korea. Caution is needed when applying this finding to patients with a higher level of severity in health status.
Abstract
Objectives: The goal of this study was to perform an economic analysis of a primary stenting with drug-eluting stents (DES) compared with bare-metal stents (BMS) in patients with acute myocardial infarction (AMI) admitted through an emergency room (ER) visit in Korea using population-based data. Methods: We employed a cost-minimization method using a decision analytic model with a two-year time period. Model probabilities and costs were obtained from a published systematic review and population-based data from which a retrospective database analysis of the national reimbursement database of Health Insurance Review and Assessment covering 2006 through 2010 was performed. Uncertainty was evaluated using one-way sensitivity analyses and probabilistic sensitivity analyses. Results: Among 513 979 cases with AMI during 2007 and 2008, 24 742 cases underwent stenting procedures and 20 320 patients admitted through an ER visit with primary stenting were identified in the base model. The transition probabilities of DES-to-DES, DES-to-BMS, DES-to-coronary artery bypass graft, and DES-to-balloon were 59.7%, 0.6%, 4.3%, and 35.3%, respectively, among these patients. The average two-year costs of DES and BMS in 2011 Korean won were 11 065 528 won/person and 9 647 647 won/person, respectively. DES resulted in higher costs than BMS by 1 417 882 won/person. The model was highly sensitive to the probability and costs of having no revascularization. Conclusions: Primary stenting with BMS for AMI with an ER visit was shown to be a cost-saving procedure compared with DES in Korea. Caution is needed when applying this finding to patients with a higher level of severity in health status.
참고문헌 (21)
- Kushner FG, "2009 Focused Updates: ACC", AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC, SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation, pp.American Heart Association Task Force on Practice Guidelines, Circulation[DOI]
- Nordmann AJ, "Clinical outcomes of stents versus balloon angioplasty in non-acute coronary artery disease. A meta-analysis of randomized controlled trials", Eur Heart J, 25(1), pp.69~80 (2004)
- Hill RA, "Drug-eluting stents: a systematic review and economic evaluation", Health Technol Assess, 11(46), pp.221~ (2007)
- Suh HS, "Drugeluting stents versus bare-metal stents in acute myocardial infarction: a systematic review and meta-analysis", J Technol Assess Health Care, 27(1), pp.11~22 (2011)
- Park KW, "‘Real world’ comparison of drug-eluting stents vs bare metal stents in the treatment of unselected patients with acute STsegment elevation myocardial infarction", Circ J, 74(6), pp.1111~1120 (2010)
- Examination of healthcare expenditure for patients with health insurance in 2010, "National Health Insurance Corporation. Examination of healthcare expenditure for patients with health insurance in", National Health Insurance Corporation, 172~ (2011)
- The Korea National Health and Nutrition Examination Survey (KNHANES III), "Korea Centers for Disease Control and Prevention", Korea Centers for Disease Control and Prevention, 174~177 (2005)
- "Consumer price index in transportation" (2011)[URL]
- Lord SJ, "A systematic review and economic analysis of drug-eluting coronary stents available in Australia", Med J Aust, 183(9), pp.464~471 (2005)
- Neyt M, "Cost effectiveness of drug-eluting stents in Belgian practice: healthcare payer perspective", Pharmacoeconomics, 27(4), pp.313~327 (2009)
- Ong AT, "Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: results from the RESEARCH Registry", Eur Heart J, 27(24), pp.2996~3003 (2006)
- Cho Y, "Paclitaxel- versus sirolimus-eluting stents for treatment of STsegment elevation myocardial infarction: with analyses for diabetic and nondiabetic subpopulation", JACC Cardiovasc Interv, 3(5), pp.498~506 (2010)
- Kim KH, "Comparison of drug-eluting versus bare-metal stent implantation in ST-elevation myocardial infarction patients with renal insufficiency: results from the national registry in Korea", J Cardiol, 154(1), pp.71~77 (2012)
- Park K, "Comparison of 5-year clinical outcomes between sirolimus-versus paclitaxel-eluting stent: Korean multicenter network analysis of 9000-patient cohort", Circ Cardiovasc Interv, 5(2), pp.174~184 (2012)
- Park KW, "One year clinical and six month angiographic results of drug eluting stents for ST elevation acute myocardial infarction: ‘real world’ comparison between sirolimus- and paclitaxeleluting stents", J Cardiol, 131(3), pp.350~355 (2009)
- Park KW, "Comparison between zotarolimus-eluting stents and first generation drug-eluting stents in the treatment of patients with acute ST-segment elevation myocardial infarction", J Cardiol, 166(1), pp.118~125 (2013)
- 심두선, "Effectiveness of Drug-Eluting Stents versus Bare-Metal Stents in Large Coronary Arteries in Patients with Acute Myocardial Infarction", Journal of Korean Medical Science, 26(4), pp.521~527 (2011), 대한의학회
- Strategies to improve the validity of diagnostic codes of National Health Insurance claims data, "Park BJ", Health Insurance Review and Assessment Services, 118~119 (2002)
- Brar SS, "Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis", Am Coll Cardiol, 53(18), pp.1677~1689 (2009)
- Di Lorenzo E, "Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimuseluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial", Circulation, 120(11), pp.964~972 (2009)
- Généreux P, "Are drug-eluting stents safe in the long term?", CMAJ, 180(2), pp.154~155 (2009)